Elixinol Global Limited Annual Report 2020

Consolidated Statement of Profit or Loss and Other Comprehensive Income for the year ended 31 December 2020 Group Note 2020 $’000 2019 $’000 Restated Revenue from continuing operations 5 15,010 30,714 Share of profits/(losses) of associates and joint ventures accounted for using the equity method 14 (1,076) (1,624) Other income 6 260 25 Interest income calculated using the effective interest method 100 564 Expenses Raw materials and consumables used and processing expenses (8,344) (14,370) Employee benefits expenses and Directors' fees (13,036) (14,292) Depreciation and amortisation expense 7 (3,213) (2,795) Impairment of intangibles 7 (39,178) (49,059) Impairment of assets 7 (35,008) (11,994) Professional services expenses (4,068) (5,279) Sales and marketing expenses (6,602) (11,513) Administrative expenses (4,504) (6,986) Distribution costs (570) (1,307) Finance costs 7 (49) (133) Loss before income tax benefit/(expense) from continuing operations (100,278) (88,049) Income tax benefit/(expense) 8 (4,200) 7,537 Loss after income tax benefit/(expense) from continuing operations (104,478) (80,512) Loss after income tax expense from discontinued operations 9 – (2,559) Loss after income tax benefit/(expense) for the year (104,478) (83,071) Other comprehensive income Items that may be reclassified subsequently to profit or loss Foreign currency translation 80 1,908 Share of associate other comprehensive income – (137) Other comprehensive income for the year, net of tax 80 1,771 Total comprehensive loss for the year (104,398) (81,300) Loss for the year is attributable to: Non-controlling interest 28 (143) Owners of Elixinol Global Limited (104,506) (82,928) (104,478) (83,071) F INANCI AL REPORT 36 Elixinol Global Limited | Annual Report 2020